Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752147 | 0.88 | GCGR (0.56) | ALDH1A1GCGRMAPTKDM4EHPGD | |
| SCHEMBL15481445 | 0.86 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1GCGRMAPTKDM4E | |
| SCHEMBL3843460 | 0.84 | PRKCZ (0.52) | ALDH1A1L3MBTL1GCGRMAPTKDM4E | |
| SCHEMBL28300700 | 0.83 | ADORA1 (0.47) | GCGR | |
| SCHEMBL14189840 | 0.83 | GCGR (0.40) | ALDH1A1L3MBTL1GCGRMAPTKDM4E | |
| SCHEMBL3206 | 0.83 | GCGR (0.47) | ALDH1A1L3MBTL1GCGRMAPTKDM4E | |
| SCHEMBL28302219 | 0.82 | ADORA1 (0.46) | GCGR | |
| SCHEMBL3589 | 0.82 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1GCGRMAPTKDM4E | |
| SCHEMBL8199366 | 0.82 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1GCGRMAPTKDM4E | |
| SCHEMBL8178136 | 0.82 | GCGR (0.64) | ALDH1A1L3MBTL1GCGRMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | disclosed |
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | disclosed |
| US-8318933-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD (IN) | 2012-11-27 | — | — | US | disclosed |
| US-8273878-B2 | Process for the preparation of pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2012-09-25 | — | — | US | disclosed |
| US-8212034-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8212035-B2 | Process for preparation of rosuvastatin calcium field of the invention | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8212035-B2 | Process for preparation of rosuvastatin calcium field of the invention | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | MALLELA SAMBHU PRASAD SARMA | 2011-07-21 | — | — | US | disclosed |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | MALLELA SAMBHU PRASAD SARMA | 2011-07-21 | — | — | US | disclosed |
| WO-2010038124-A1 | AN IMPROVED PROCESS FOR PREPARING PYRIMIDINE PROPENALDEHYDE | AUROBINDO PHARMA LIMITED (IN) | 2010-04-08 | — | — | WO | disclosed |
| EP-2088142-A2 | Compounds and Processes | AstraZeneca UK Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| US-7524955-B2 | Process for the preparation of pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2009-04-28 | — | — | US | disclosed |
| WO-2008096257-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008059519-A2 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES OF ROSUVASTATIN | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059519-A2 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES OF ROSUVASTATIN | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
| US-20060052604-A1 | Process for the Preparation of Pyrimidine Compounds | ASTRAZENECA UK LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| EP-1578731-A2 | PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS | AstraZeneca UK Limited (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004054986-A2 | PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| US-5260440-A | Anticholesterol agents | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-11-09 | — | — | US | disclosed |
| EP-0521471-A1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | DPYD, NOX4, RPIA | ALDH1A1 36/4885L3MBTL1 4721/4885GCGR 2274/4885 |
| US-20060052604-A1 | Process for the Preparation of Pyrimidine Compounds | DPYD, RIOX2, CCNE1 | ALDH1A1 2286/4885L3MBTL1 4575/4885GCGR 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.